Macro­Gen­ics chief Scott Koenig de­tails the up­beat can­cer drug da­ta from 2 pro­grams that drove a big spike in their share price

Macro­Gen­ics $MGNX dropped their AS­CO ab­stracts on 2 key drug pro­grams on Wednes­day evening, high­light­ing some ad­di­tion­al de­tails on da­ta that spurred their share …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.